Abstract
Significant interest in synthetic oligonucleotides is largely determined by their ability to form specific complexes — duplexes and/or triplexes — with nucleic acid targets of interest, primarily DNA and RNA molecules. The high specificity of these interactions is governed mainly by the formation of proper Watson-Crick and Hoogsteen hydrogen bonds between heterocyclic bases of targeted nucleic acids and the oligonucleotide ligands. This type of selective recognition of genetic information carriers can potentially open up promising new opportunities in modern rational drug design and drug discovery, as well as in the creating of powerful molecular biological and biochemical tools allowing regulation of gene expression and studying of gene functions. However, several very important problems need to be resolved before oligonucleotides may become pharmaceutical agents. Among these are increase of thermodynamic stability of the complexes formed by the oligomers with the targets, specificity of interaction with chosen molecules, hydrolytic stability and bioavailability of oligonucleotides in cells and in model animal systems as well as in human tissues and organs. Additionally, the chemical structure of the oligonucleotides and the choice of suitable and functionally meaningful molecular targets, as well as administration or delivery methods may play a crucial role in the success of oligonucleotide based therapeutic approaches.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Eckstein, F. (1966). Nucleoside phosphorothioates. J. Am. Chem. Soc. 88, 4292–4293.
Eckstein, F. (1985). Nucleoside phosphorothioates. Annual Rev. Biochem. 54, 367–402.
Stec, W. J., Zon, G., Egan, W. and Stec, B. J. (1984). Automated solid phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106, 6077–6079.
Zon, G. and Stec, W. J. (1991). In Eckstein, F. (Ed.) Oligonucleotides and Analogues: A Practical Approach, IRL Press, Oxford, UK, 87–108.
Glaser, V. (1996). Oligonucleotide therapies move toward efficacy trials to treat HIV, CMV, cancer. Genetic Engineering News 16, February 1, 1–21.
Roush, W. (1997). Antisense aims for a renaissance. Science 276, 1192–1193.
Kebler-Herzog, L., Zon, G., Uznanski, B., Whittier, G. and Wilson, W. D. (1991). Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res. 19, 2979–2986.
Koziolkiewicz, M., Krakowiak, A., Kwinkowski, M., Boczkowska, M. and Stec, W. J. (1995). Stereodifferentiation — the effect of P chirality of oligonucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res. 23, 5000–5005.
Xodo, L., Alunni-Fabbroni, M., Manzini, G. and Quadrifoglio, F. (1994). Pyrimidine phosphorothioate oligonucleotides form triple-stranded helices and promote transcription inhibition. Nucleic Acids Res. 22, 3322–3330.
Latimer, L., Hampel, K. and Lee, J. S. (1989). Synthetic repeating sequence DNAs containing phosphorothioates: nuclease sensitivity and triplex formation. Nucleic Acids Res. 17, 1549–1561.
Hacia, J. G., Wold, B. and Dervan, P. B. (1994). Phosphorothioate oligonucleotide-directed triple helix formation. Biochemistry 33, 5367–5369.
Kim, S.-G., Tsukahara, S., Yokoyama, S. and Takaku, H. (1992). The influence of oligodeoxyribonucleotide phosphorothioate pyrimidine strands on triplex formation FEBS Lett. 314, 29–32.
Svinarchuk, F., Debin, A., Bertrand, J.-R. and Malvy, C. (1996). Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 proto-oncogene promoter. Nucleic Acids Res. 24, 295–302.
Miller, P.S., Yano, J., Yano, E., Carrol, C., Jayraman, K. and Ts’o, P. O. P. (1979). Nonionic nucleic acid analogues. Synthesis and characterization of deoxyribonucleoside methylphosphonates. Biochemistry 18, 5134–5143.
Miller, P.S. (1991). Oligonucleotide methylphosphonates as antisense reagents. Bio/Technology 9, 358–361.
Miller, P. S., Dreon, N., Pulford, S. M. and McParland K. B. (1980). Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phospho-diester backbone. J. Biol. Chem. 255, 9659–9665.
Kibler-Herzog, L., Zon, G., Mizan, S. and Wilson, W. D. (1993). Stabilities of duplexes and triplexes of dA19+dT19 with alternating methylphosphonate and phosphodiester linkages. Anti-Cancer Drug Design 8, 65–79.
Trapane, T., Hogrefe, R. I., Reynolds, M. A., Kan, L.-S. and Ts’o, P. O. P. (1996). Interstrand complex formation of purine oligonucleotides and their nonionic analogues: the model system of d(AG)8 and its complement, d(CT)8. Biochemistry 35, 5495–5508.
Reynolds, M. A., Arnold, L. J., Jr., Almazan, M. T., Beck, T. A., Hogrefe, R. I., Metzler, M. D., Stoughton, S. R., Tseng, B. Y., Trapane, T., Ts’o, P. O. P. and Woolf, T. M. (1994). Triple-strand-forming methylphosphonate oligodeoxynucleotides targeted to mRNA efficiently block protein synthesis. Proc. Natl. Acad. Sci. USA 91, 12433–12437.
Letsinger, R. L., Singman, C. N., Histand, G. and Salunkhe, M. (1988). Cationic oligonucleotides. J. Am. Chem. Soc. 110, 4470–4471.
Chaturvedi, S., Horn, T. and Letsinger, R. L. (1996). Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages. Nucleic Acids Res. 24, 2318–2323.
Dagle, J. M. and Weeks, D. L. (1996). Positively charged oligonucleotides overcome potassium-mediated inhibition of triplex DNA formation. Nucleic Acids Res. 24, 2143–2149.
Cheng, A.-J. and Van Dyke, M. W. (1993). Monovalent cation effects on intermolecular purine-purine-pyrimidine triple-helix formation. Nucleic Acids Res. 21, 5630–5635.
Mignet, N. and Gryaznov, S. M. (1998). Zwitterionic oligodeoxyribonucleotide N3′ →P5′ phosphoramidates: synthesis and properties. Nucleic Acids Res. 26, 431–438.
Gryaznov, S. and Chen, J.-K. (1994). Oligodeoxyribonucleotide N3′→P5′ phosphoramidates: synthesis and hybridization properties. J. Am. Chem. Soc. 116, 3143–3144.
Gryaznov, S. M., Lloyd, D.H., Chen, J.-K., Schultz, R. G., DeDionisio, L. A., Ratmeyer, L. and Wilson, W. D. (1995). Oligonucleotide N3′→P5′ phosphoramidates. Proc. Natl. Acad. Sci. USA 92, 5798–5802.
Chen, J.-K., Schultz, R. G., Lloyd, D. H. and Gryaznov, S. M. (1995). Synthesis of oligodeoxyribonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res. 23, 2661–2668.
Gryaznov, S. M. (1997). Synthesis and properties of the oligonucleotide N3′→P5′ phosphoramidates. Nucleosides & Nucleotides 16, 899–905.
Ding, D., Gryaznov, S. M., Lloyd, D. H., Chandrasekaran, S., Yao, S., Ratmeyer, L., Pan, Y. and Wilson, W. D. (1996). An oligodeoxyribonucleotide N3′→P5′ phosphoramidate duplex forms an A-type helix in solution. Nucleic Acids Res. 24, 354–360.
Tereshko, V., Gryaznov, S. and Egli, M. (1998). Consequences of replacing the DNA 3′-oxygen by an amino group: high resolution crystal structure of a fully modified N3′ →P5′ phosphoramidate DNA dodecamer duplex. J. Am. Chem. Soc. 120, 269–283.
Escudé, C., Giovannangeli, C., Sun, J.-S., Lloyd, D.H., Chen, J.-K., Gryaznov, S. M., Garestier, T. and Hélène, C. (1996). Stable triple helices formed by oligonucleotide N3′→P5′ phosphoramidates inhibit transcription elongation. Proc. Natl. Acad. Sci. USA 93, 4365–4369.
Roberts, R. W. and Crothers, D.M. (1992). Stability and properties of double and triple helices: dramatic effects of RNA or DNA backbone composition. Science 258, 1463–1466.
Shimizu, M., Konishi, A., Shimada, Y., Inoue, H. and Ohtsuka, E. (1992). Oligo(2′-O-methyl)ribonucleosides. Effective probes for duplex DNA. FEBS Lett. 302, 155–158.
Guschlbauer, W. and Jankowski, K. (1980). Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Res. 8, 1421–1433.
Semerad, C. L. and Maher, L. J., III. (1994). Exclusion of RNA strand from a purine motif triple helix. Nucleic Acids Res. 22, 5321–5325.
Giovannangeli, C., Perrouault, L., Escudé, C., Gryaznov, S. and Hélène, C. (1996). Efficient inhibition of transcription elongation in vitro by oligonucleotide phosphoramidates targeted to proviral HIV DNA. J. Mol. Biol. 261, 386–398.
Giovannangeli, C., Diviacco, S., Labrousse, V., Gryaznov, S., Chameau, P. and Hélène, C. (1997). Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94, 79–84.
Zhou-Sun, B.-W., Sun, J.-S., Gryaznov, S. M., Liquier, J., Garestier, T., Hélène, C. and Taillandier, E. (1997). A physico-chemical study of triple helix formation by an oligothymidylate with N3′→P5′ phosphoramidate linkages. Nucleic Acids Res. 25, 1782–1787.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gryaznov, S.M. (1999). Triple Helix Formation with Modified Oligonucleotides. In: Malvy, C., Harel-Bellan, A., Pritchard, L.L. (eds) Triple Helix Forming Oligonucleotides. Perspectives in Antisense Science, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5177-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5177-5_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7358-2
Online ISBN: 978-1-4615-5177-5
eBook Packages: Springer Book Archive